QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient

Trial Profile

QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms QDISS Stud
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 1 Nov 2019 to 1 May 2020.
    • 13 Sep 2017 Planned primary completion date changed from 7 Jun 2019 to 7 Oct 2019.
    • 28 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top